BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW
Biofrontera Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.81−0.02 (-1.94%)
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
Biofrontera Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Product [Member] | – | – | – | $24.04M | $18.79M | – | – |
| Revenues Related Party [Member] | – | – | – | $57.00K | $62.00K | – | – |
| Ameluz LSA [Member] | – | – | $150.00M | – | – | – | – |
| Second A&R Ameluz LSA [Member] | – | $150.00M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biofrontera's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.